… ARDS susceptibility and outcomes to date (modified from Guillen-Guio et al. [33]). Genes …
with ARDS susceptibility and outcomes to date (modified from Guillen-Guio et al. [33]). Genes …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with
high mortality, uncertain cause, and few treatment options. Studies have identified a significant …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterized by
scarring of the lung that is believed to result from an atypical response to injury of the …

… The next published GWAS in the timeline was conducted by Guillen-Guio and colleagues
[27] on European patients with sepsis-induced ARDS. This study supported that variants in …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition with poor survival times. We
previously published a genome-wide meta-analysis of IPF risk across three studies with …

… b Phased data are needed for the ancestral populations and unphased data for the
admixed population. CRF (Conditional Random Field), HMM (Hidden Markov Model), LD (linkage …

Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease characterised by
progressive scarring leading to alveolar stiffness, reduced lung capacity, and impeded gas …

The research of rare and devastating orphan diseases, such as idiopathic pulmonary
fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor—the …

… B. Guillen-Guio is supported by Wellcome Trust grant 221680/Z/20/Z. For the purpose of
open access, the author has applied a CC BY public copyright licence to any author accepted …

… B) Mean (SD) FLT1 promoter activity of vector constructs in A549 and THP-1 cells. The FLT1
intron 10 fragment harbours the reference alleles. C) Mean (SD) FLT1 promoter activity of …